MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/nau.70199

Медицинская библиотека · Neurourology and urodynamics · 2025

Bladder Function and Safety of Vibegron in Men With Overactive Bladder Receiving Treatment for Benign Prostatic Hyperplasia: Outcomes From the Phase 3 Randomized Controlled COURAGE Trial.

Rovner Eric S, Owens-Grillo Janet, Thomas Elizabeth, Herschorn Sender, Peters Kenneth M, Staskin David, Mujais Salim

СтатьяРандомизированное исследованиеКлиническое исследование III фазыМногоцентровое исследованиеПеревод в очереди

Аннотация

PURPOSE: Vibegron was associated with improvements in efficacy versus placebo and was well tolerated in men with overactive bladder (OAB) on pharmacotherapy for benign prostatic hyperplasia (BPH) in the COURAGE trial (NCT03902080). Additional safety, bladder function, and urodynamics data are provided.

METHODS

This 24-week, phase 3, double-blind, placebo-controlled trial randomized men ≥ 45 years with OAB and BPH receiving α-blocker ± 5α-reductase inhibitors to once-daily vibegron or placebo (1:1). From the safety analysis set (SAF), postvoid residual urine volume (PVR), maximum urinary flow rate (Uroflow-Qmax), International Prostate Symptom Score (IPSS) total score, and urologic-related adverse events (AEs) were collected throughout the trial. Qmax and detrusor pressure at Qmax (PdetQmax) were collected at baseline and week 12 in a urodynamics substudy (urodynamics evaluable set [UES]).

RESULTS

In the SAF, differences between vibegron (n = 553) and placebo (n = 551) in PVR and Uroflow-Qmax were minimal at baseline, week 12, and week 24. Mean (SD) change from baseline (CFB) at week 24 in IPSS total score was -7.3 (6.96) with vibegron and -5.7 (7.14) with placebo. Urinary retention was reported as an AE for 5 (0.9%) and 4 (0.7%) participants receiving vibegron and placebo, respectively. In the UES (vibegron, n = 21; placebo, n = 22), least squares mean difference (95% CI) between vibegron and placebo in CFB at week 12 was 2.75 (0.16, 5.34) mL/s in Qmax and 2.86 (-13.52, 19.25) cmH2O in PdetQmax.

CONCLUSIONS

There were no safety signals related to bladder function identified by urodynamics; risk of protocol-defined AEs of urinary retention or residual urine volume increase was not increased with vibegron compared with placebo in this population.

CLINICAL TRIAL REGISTRATION: This study is registered at www.

CLINICALTRIALS: gov. The registration identification number is NCT03902080.

Для цитирования: Rovner Eric S, Owens-Grillo Janet, Thomas Elizabeth, Herschorn Sender, Peters Kenneth M, Staskin David, Mujais Salim. Bladder Function and Safety of Vibegron in Men With Overactive Bladder Receiving Treatment for Benign Prostatic Hyperplasia: Outcomes From the Phase 3 Randomized Controlled COURAGE Trial.. Neurourology and urodynamics. 2025. DOI: 10.1002/nau.70199.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.